Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry. This month, MassBio spoke with Nathaniel “Sandy” Paige, CEO, Explora BioLabs.
An excerpt of the interview is below. For the full interview, go here.
Q: Tell us about your organization, its mission, and current initiatives.
Explora BioLabs supports innovative, life-changing in vivo studies with turnkey vivarium facilities, management, and related industry-leading services—what we call Vivarium-as-a-Service. Our motto—“Your Science: Powered By Explora”—tells the story most simply: we provide the Ph.D.-backed facilities and supporting research services that allow scientists to stay focused on their studies. Explora handles the rest.
We understand that preclinical success requires efficiency and flexibility supported by a collaborative and trusting community. We have a commitment to deliver the highest-quality spaces, skilled people, and robust compliance and care expertise to help research teams and growing U.S. biotechs achieve health-extending discoveries. We maintain this focus even as we expand to regions where new biotechs are establishing themselves.
Q: How do your organization’s activities help patients now and into the future?
A: The preclinical in vivo work we do is a fundamental part of drug development. Doing it well encompasses many things: ethics, welfare, quality, repeatability, and more. These elements, when cared for properly, help drugs succeed or fail faster than when they are not.
The accessible, quality research environments and Ph.D-level oversight that Explora provides are essential to biotechs that need to move quickly with repeatable, trustable results. Biotechs can’t wait months or years to start their studies. Our goal is to place facilities within a 5 to 10-minute drive of their offices and to get them operating in an Explora facility within two weeks.
With our help, clients can do more, faster than if they were working alone. That means that proven life-saving drugs get delivered to patients faster.
For the full interview, go here.
